Implementation of Risk-Based Inspections of Pharmaceutical Premises

The Pharmacy and Poisons Board (PPB) of Kenya has announced the implementation of risk-based inspections for pharmaceutical premises, including wholesalers and retail pharmacies, commencing with the 2026 licensing cycle. This strategic shift aims to enhance regulatory oversight by focusing resources on higher-risk areas, ensuring compliance with Good Storage and Distribution Practices (GSDP) and other applicable regulatory requirements. The new approach, rooted in the Pharmacy and Poisons Act, Cap 244, and aligned with World Health Organization (WHO) guidelines, seeks to bolster the quality, safety, and efficacy of Health Products and Technologies (HPTs) in Kenya. Practitioners must now prepare for inspections that will classify deficiencies, with critical or numerous major findings leading to non-compliance.

The pharmaceutical landscape in Kenya is undergoing a significant transformation with the Pharmacy and Poisons Board (PPB) adopting a risk-based approach to the inspection of pharmaceutical premises. This pivotal change, officially announced through a Public Notice, marks a departure from traditional inspection methodologies, promising a more efficient and targeted regulatory framework. The move is designed to optimize the allocation of regulatory resources, focusing on areas that pose the greatest potential risk to public health and the integrity of the pharmaceutical supply chain.

This article delves into the implications of the PPB's new inspection regime for legal and pharmaceutical professionals in Kenya. It will explore the statutory underpinnings, the practical aspects of the risk-based methodology, and the critical steps practitioners must take to ensure compliance. The shift underscores the PPB's commitment to aligning its regulatory practices with international best standards, ultimately safeguarding the quality, safety, and efficacy of Health Products and Technologies (HPTs) available to the Kenyan populace.

The implementation of risk-based inspections during the 2026 licensing cycle will impact manufacturers, importers, distributors, wholesalers, and retail pharmacies alike, necessitating a thorough understanding of the revised compliance expectations and inspection criteria.

The Pharmacy and Poisons Board (PPB) is the primary regulatory authority overseeing the pharmaceutical sector in Kenya, established under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya. This Act empowers the Board to control the profession of pharmacy and the trade in drugs and poisons, with a mandate to protect and promote public health by ensuring access to quality, safe, and efficacious HPTs. Historically, the PPB has conducted routine inspections to verify compliance with the provisions of the law and various regulatory requirements, including Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP).

Sections 45 and 47 of the Pharmacy and Poisons Act, Cap 244, explicitly grant authorized officers of the Board the power to enter and inspect pharmaceutical premises and to demand access to licenses, records, and other regulatory documentation. Any obstruction of these officers in their lawful duties constitutes an offence under the Act. Over time, the PPB has also developed and published comprehensive guidelines, such as the Kenya Good Manufacturing Practices Guidelines, which are periodically updated in line with World Health Organization (WHO) standards, reflecting an ongoing commitment to international best practices. The transition to risk-based inspections represents an evolution of this regulatory framework, aiming to enhance efficiency and effectiveness in an increasingly complex pharmaceutical market.

The PPB's Public Notice on the "Implementation of Risk-Based Inspections of Pharmaceutical Premises" clarifies that, starting with the 2026 licensing cycle, inspections for wholesalers and retail pharmacies will be conducted on a risk-based approach. This approach is designed to assess compliance with Good Storage and Distribution Practices (GSDP) and other applicable regulatory requirements. The framework for these inspections will draw upon the Pharmacy and Poisons Act, Cap 244, its subsidiary legislation, national guidelines issued by the Board, and specifically references the World Health Organization (WHO) Technical Report Series (TRS) 1025, Annex 7: Good Storage and Distribution Practices for Medical Products.

Under this new system, compliance will be determined by the nature and quantity of deficiencies identified during an inspection. Premises will be deemed non-compliant if critical deficiencies are found, or if more than seven major deficiencies are identified. This classification system introduces a more objective and structured method for evaluating compliance, moving beyond a simple pass/fail to a nuanced assessment of risk. Critical deficiencies typically refer to those that pose an immediate or direct threat to public health, while major deficiencies indicate a significant deviation from GSDP or other regulatory requirements that could compromise the quality, safety, or efficacy of HPTs.

The adoption of WHO TRS 1025, Annex 7, underscores Kenya's commitment to harmonizing its regulatory standards with international benchmarks. This alignment is crucial for facilitating trade and ensuring that pharmaceutical products circulating within Kenya meet globally recognized quality standards. The risk-based model allows the PPB to strategically deploy its limited inspection resources, focusing on entities or processes that present a higher inherent risk, such as those handling sensitive products, having a history of non-compliance, or operating complex distribution networks. This contrasts with a uniform inspection schedule, which might disproportionately allocate resources to low-risk entities.

For practitioners, this shift necessitates a proactive and comprehensive internal audit system to identify and mitigate potential deficiencies before an official inspection. Understanding the criteria for critical and major deficiencies, as outlined in the PPB's guidelines and the referenced WHO documents, becomes paramount. The emphasis on GSDP means that storage conditions, inventory management, transportation, and documentation practices will be under heightened scrutiny. Failure to adapt to this risk-based paradigm could result in severe regulatory actions, including the suspension or revocation of operating licenses and closure of premises, as the PPB has historically demonstrated a firm stance against non-compliant practices.

The implementation of risk-based inspections by the Pharmacy and Poisons Board marks a significant evolution in Kenya's pharmaceutical regulatory landscape. This strategic move, effective from the 2026 licensing cycle, is poised to enhance the efficiency and effectiveness of regulatory oversight, ensuring that Health Products and Technologies in Kenya consistently meet stringent quality, safety, and efficacy standards. For pharmaceutical practitioners, this is a clear call to action to re-evaluate and strengthen their internal compliance systems, particularly concerning Good Storage and Distribution Practices.

Legal professionals advising clients in the pharmaceutical sector must guide them in understanding the nuances of this new inspection regime, including the classification of deficiencies and the adoption of international guidelines like WHO TRS 1025, Annex 7. Proactive engagement with the PPB's guidelines, robust internal audits, and continuous training for personnel on GSDP will be crucial for maintaining compliance and avoiding regulatory penalties. The industry should anticipate a more focused and rigorous inspection process, demanding a higher level of preparedness and a sustained commitment to quality assurance throughout the supply chain.